| 引用本文: | 王海岛,林映,郑俊刚.痰热清注射液联合孟鲁司特钠对支原体肺炎患儿的影响[J].中国现代应用药学,2020,37(8):999-1003. |
| WANG Haidao,LIN Ying,ZHENG Jungang.Effect of Tanreqing Injection and Montelukast Sodium Tablets on Children with Mycoplasma Pneumonia[J].Chin J Mod Appl Pharm(中国现代应用药学),2020,37(8):999-1003. |
|
| 摘要: |
| 目的 研究痰热清与孟鲁司特钠联合治疗法对支原体肺炎患儿临床疗效、血气及肺功能指标的影响。方法 选取2017年3月-2019年2月收治的支原体肺炎患儿，按照治疗方法不同分为观察组（n=46）与对照组（n=47）。给予2组患儿同等常规阿奇霉素治疗，观察组在阿奇霉素基础上增加了痰热清与孟鲁司特钠联合用药，对照组增加了孟鲁司特钠。观察2组患儿各临床症状消失时间、临床疗效、不良反应发生率、肺功能指标和血气分析指标动脉血氧分压（PaO2）、动脉血二氧化碳分压（PaCO2）、动脉血氧饱和度（SaO2）。结果 观察组临床总显效率为95.65%，明显高于对照组的65.96%（P<0.05）。观察组咳嗽、发热、喘息、肺部湿啰音消失时间均短于对照组（P<0.05）。观察组治疗1，2周后PaO2水平明显高于对照组（P<0.05），PaCO2水平明显低于对照组（P<0.05）；观察组治疗1周后SaO2水平明显高于对照组（P<0.05）。观察组总不良反应发生率为8.70%，明显低于对照组的34.04%。观察组治疗2周后FVC、FEV、MPEF均高于对照组（P<0.05）。结论 痰热清与孟鲁司特钠联合治疗能明显缩短支原体肺炎患儿各临床症状缓解时间，恢复各血气指标水平，减少不良反应。 |
| 关键词: 痰热清注射液 孟鲁司特钠 支原体肺炎 血气指标 |
| DOI：10.13748/j.cnki.issn1007-7693.2020.08.021 |
| 分类号:R969.4 |
| 基金项目: |
|
| Effect of Tanreqing Injection and Montelukast Sodium Tablets on Children with Mycoplasma Pneumonia |
|
WANG Haidao, LIN Ying, ZHENG Jungang
|
|
Pediatrics of Haikou Maternal and Child Health Hospital, Haikou 570203, China
|
| Abstract: |
| OBJECTIVE To investigate the effect of Tanreqing injection and montelukast sodium tablets on symptoms and blood gas index and pulmonary function of children with mycoplasma pneumonia. METHODS Children with mycoplasma pneumonia admitted to hospital from March 2017 to February 2019 were enrolled, and randomly divided into two groups, observation group(n=46) and control group(n=47). Both groups were given routine azithromycin treatment, based on this, observation group received the Tanreqing injection and montelukast sodium tablets, control group received the montelukast sodium tablets. The remission time of clinical symptoms, clinical efficacy, incidence of adverse reactions, lung function index, blood gas indexes including arterial partial pressure of oxygen(PaO2), arterial partial pressure of carbon dioxide(PaCO2) and arterial oxygen saturation(SaO2), pulmonary function at admission and 2 weeks after treatment were observed. RESULTS The total clinical response rate of the observation group was significantly higher than that of the control[95.65% vs 65.96%, P<0.05]. The remission time of symptoms such as cough, fever, wheezing and moist rale in the observation group were shorter than those in the control group(P<0.05). After 1, 2 weeks of treatment in the observation group, PaO2 levels were significantly higher than that in the control group(P<0.05), PaCO2 levels were significantly lower than that in the control group(P<0.05); after 1 week of treatment in the observation group, SaO2 levels were significantly higher than that in the control group(P<0.05). The incidence of total adverse reactions in the observation group was significantly lower than that in the control group[8.70% vs 34.04%]. At post-treatment 2 week, levels of FVC, FEV and MPEF in the two groups were increased in both groups, and were higher in the observation group than in the control group(P<0.05). CONCLUSION Application of Tanreqing injection and montelukast sodium tablets based on routine treatment can effectively shorten the remission time of clinical symptoms, restore the blood gas index level and reduce adverse reactions in children with mycoplasma pneumonia. |
| Key words: Tanreqing injection montelukast sodium tablets mycoplasma pneumonia blood gas index |
